Disease Diagnosis TRIZ Cases

Antibody-based capture of vimentin-positive circulating tumor cells improves recurrence prediction accuracy beyond standard radiological staging.

Lipid-drug complexes mitigate potassium channel blockade risks, preventing QT interval prolongation and arrhythmias.

Detecting desmosomal protein mislocalization in buccal cells diagnoses arrhythmogenic cardiomyopathy without invasive endomyocardial biopsy.

A hyaluronan-based assay detects heavy chain complexes to quantify local inflammatory activity in synovial fluid samples.

Replacing classical cardiac markers with provasopressin resolves sensitivity and specificity trade-offs for early acute coronary syndrome diagnosis.

Segment complex biological mechanisms into distinct mitogenic, anti-apoptotic, and regenerative assays to ensure batch-to-batch consistency.

A diagnostic method detects cholemia by measuring red blood cell resistance to osmotic lysis in a salt solution.

Replacing clinical staging with immune marker quantification resolves the contradiction between prediction accuracy and method complexity.

Segmented RNA profiling detects HER2 status changes to resolve monitoring precision issues in breast cancer treatment.

Quantitative immunofluorescence measures BCL6, VEGF, and CD68 protein levels in patient samples to determine diffuse large B-cell lymphoma prognosis.

ASPM, CENPF, GTSE1, PGK1, RACGAP1, and TK1 biomarker analysis predicts chemotherapy resistance to guide personalized treatment strategies.

Glutathionylation of cysteine 45 on the erythrocyte Na+K+ pump beta subunit enables early cardiovascular disease detection before myocardial damage occurs.

A prediction system measures TNF-alpha inhibitor concentrations to forecast autoantibody formation during therapy.

IL-1β quantification in gingival crevicular fluid segments patients into slow and high responders, enabling targeted antimicrobial or anti-inflammatory therapy.

Pre-incubating patient samples with DFS70 derived antigen complexes interfering antibodies, reducing false positive rates in autoimmune disease assays.

Patient-specific induced neuronal progenitor cells replace homogeneous animal models to resolve clinical trial heterogeneity and improve predictive accuracy.

Nucleic acid aptamers target microvesicle surface antigens, resolving low specificity in cancer diagnostics.

A multiplex immunoassay detects adiponectin and IL-1Ra polypeptides to differentiate diabetic conditions.

SRM/MRM assays quantify DR5 protein in formalin-fixed tissues via specific peptide detection, overcoming low signal intensity from proteolytic modifications.

Analyzing intact nucleosome levels across menstrual phases detects endometriosis, resolving the trade-off between diagnostic accuracy and patient trauma.

A diagnostic kit uses specific AQP-4 polypeptide fragments to detect IL-4 secreting T-cells in peripheral blood samples.

An ultra-sensitive chemiluminescence assay detects fasting growth hormone levels to predict cardiovascular risk.

Antibodies detect selective zeta chain downregulation to assess immune status in chronic inflammatory diseases.

Nasal mucosa IgA ratio measurement resolves blood antibody limitations by enabling precise influenza infection risk prediction and vaccine evaluation.

CXCL12 polypeptide and FoxP3 biomarkers resolve low sensitivity in early cancer detection by enabling precise molecular staging.

Calculating response curve slopes and curvatures cancels baseline variations to enable early acute myocardial infarction diagnosis.

Combining CETP inhibitors with tamoxifen overcomes endocrine resistance in refractory breast cancer.

A 1,5-anhydroglucitol biomarker quantifies glycogen storage disease status through concentration measurement.

Calcium binding mutants of S100A12 form stable dimers to differentiate dimeric forms from tetramers and hexamers in inflammatory disease diagnostics.

A multi-coated test surface captures diverse food antigens to detect specific IgG, IgA, and C1q binding in a single assay.

Engineered chimeric anti-IgG4 antibodies eliminate cross-reactivity with other immunoglobulin subclasses during turbidity-based quantification.

Pre-fixed eukaryotic cells expressing adult and fetal acetylcholine receptors replace radioactive assays to increase immunofluorescence sensitivity.

Analyzing urine for integrin and talin levels replaces invasive kidney biopsies, enabling accurate FSGS diagnosis.

Segments type I, II, and III collagen antibody measurements to resolve the contradiction between autoimmune disease interference and accurate cancer diagnosis.

Measuring SPDEF, ARG2, and ABEP1 levels guides surgical margin assessment to prevent recurrence without increasing treatment complexity.

Measuring SPARC levels in cancer-associated fibroblasts stratifies triple-negative breast cancer risk, enabling targeted therapy to inhibit tumor progression.

Replacing complex cell line generation with recombinant HLA-coated magnetic beads isolates donor-specific antibodies for accurate organ transplant matching.

Quantifying serum protein biomarkers enables precise monitoring of disease progression and treatment response without invasive central nervous system sampling.

MGL-nanoparticles bind altered CA125 glycosylation patterns to differentiate epithelial ovarian cancer from benign conditions.

Measuring human growth hormone levels in blood samples identifies patients with elevated vascular risk.

A urine biomarker panel detects specific proteins to identify bladder cancer in female patients.

Covalent phospholipid attachment prevents detergent-induced signal loss, ensuring stable antibody detection.

Biochemical assays detect hydrosalpinx through blood plasma biomarkers, replacing invasive laparoscopy with non-invasive fluid analysis.

Whole blood diagnostic kit preserves feedback mechanisms via merging principles, improving functional analysis reliability.

Assays measuring cardiac troponin T and NT-proBNP levels identify patients at risk for heart failure.

Measuring apoA-IV concentrations detects slight renal damage when conventional markers like serum creatinine remain normal.

Recombinant antibodies bind native LOX-1 epitopes to neutralize signaling, resolving absent neutralizing activity in existing therapies.